Treatments in the pipeline

Find out more about new potential treatments for MS that are currently in phase 2 (mid stage) or phase 3 (late stage) clinical trials. These treatments aren't available yet, but have reported promising results.

Keep coming back to read about the latest updates and newest potential treatments for:

Why clinical trials?

It’s important that potential treatments for MS are tested in clinical trials to make sure they're safe and effective. There are three phases of clinical trials before a treatment can be licensed.

Around one in 10 potential treatments makes it through all three phases of clinical trials.

>>Read more about the research process

Potential treatments for relapsing MS

Phase 3

Cladribine

Cladribine is an oral medication that works by reducing the number of immune cells in the body.

HSCT

HSCT is an intense chemotherapy treatment for MS.

Laquinimod

Laquinimod is a tablet that is thought to stop immune cells reaching the brain.

Ocrelizumab

Ocrelizumab is an intravenous infusion that targets cells of the immune system.

Ofatumumab

Ofatumumab is an injectable drug that can alter the behaviour of certain immune cells.

Ozanimod (RPC-1063)

Ozanimod (otherwise known as RPC-1063) is an oral treatment thought to prevent a subset of immune cells from entering the brain and spinal cord.

Ponesimod

Ponesimod is an oral treatment that might stop immune cells reaching the brain.

Phase 2

Amiselimod

Amiselimod is an oral treatment that alters the behavior of immune cells.

Anti-LINGO-1

Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.

ATL1102

ATL1102 is an injection that prevents immune cells reaching the brain and spinal cord.

ATX-MS-1467

ATX-MS-1467 is an injection that aims to 'switch off' the immune system's attack on myelin.

Clemastine

Clemastine is an oral treatment that has been shown to suppress the immune system and may promote myelin repair.

Lipoic acid

Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain and could protect nerves from damange.

Minocycline

Minocycline is an oral antibiotic currently used to treat bacterial infections and can prevent inflammation.

Raltegravir

Raltegravir is an oral antiretroviral drug that can fight viral infections.

Vatelizumab

Vatelizumab is an infusion that prevents certain immune cells from building up at sites of inflammation in MS.

Rituximab

Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.

Back to top

Potential treatments for primary progressive MS

Phase 3 

Ocrelizumab

Ocrelizumab is an intravenous infusion that kills certain immune cells.

MD1003

MD1003 is a tablet that could promote myelin repair.

Masitinib

Masitinib is an oral treatment that blocks some of the body's immune responses.

Fingolimod

Fingolimod is an oral treatment that stops certain immune cells from reaching the brain.

Phase 2

Fluoxetine

Fluoxetine is already licensed to treatment depression. It's being tested for people with primary and secondary progressive MS.

HSCT

HSCT is an intense chemotherapy treatment for MS.

Ibudilast

Ibudilast (also known as MN-166) is a tablet thought to reduce inflammation and to protect against cell death, which could help to reduce nerve cell loss in MS.

Laquinimod

Laquinimod is a tablet that is thought to stop immune cells reaching the brain.

Natalizumab

Also known as Tysabri, natalizumab stops immune cells from entering the brain and spinal cord.

Rituximab

Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.

Back to top

Potential treatments for secondary progressive MS

Phase 3

MD1003

MD1003 is an tablet that could promote myelin repair.

Masitinib

Masitinib is an oral treatment that blocks some of the body's immune responses.

Simvastatin

Simvastatin is an oral treatment that could protect nerves from damage.

Siponimod

Siponimod is an oral treatment that stops immune cells from reaching the brain.

Phase 2

Amiloride

Amiloride is already licensed to treat heart disease. It's being tested in a clinical trial called MS-SMART for people with secondary progressive MS.

Anti-LINGO-1

Anti-LINGO-1 is an intravenous infusion that could promote myelin repair.

Fluoxetine

Fluoxetine is already licensed to treat depression. It's being tested in a clinical trial called MS-SMART for people with secondary progressive MS.

HSCT

HSCT is an intense chemotherapy treatment for MS.

Ibudilast

Ibudilast (also known as MN-166) is a tablet that could reduce inflammation and protect against cell death, which may help to reduce nerve cell loss in MS.

Lipoic acid

Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain and could protect nerves from damage.

MIS416

MIS416 is an infusion that is thought to alter the behaviour of certain immune cells in MS.

MS-SMART

MS-SMART is a trial involving three oral treatments - amiloride, fluoxetine and riluzole - that could protect nerves from damage.

Natalizumab

Also known as Tysabri, natalizumab stops immune cells from entering the brain and spinal cord.

Riluzole

Riluzole is licensed to treat motor neurone disease (MND). It's being tested in a clinical trial called MS-SMART for people with secondary progressive MS.

Tcelna

Tcelna is an injectable treatment that uses a person's own immune cells to alter the behaviour of the immune system in MS

Rituximab

Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.

Back to top

Potential treatments for optic neuritis

Phenytoin

Phenytoin is an oral treatment that has been shown to have the potential to protect nerve cells in the brain and spinal cord.

Anti-LINGO-1

Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.

Amiloride

Amiloride is licensed to treat heart disease. It could protect nerves from damage.

MD1003

MD1003 is a tablet that could promote myelin repair.

Treatments already licensed

There are currently 12 licensed treatments for people with relapsing MS along with several symptom management treatments for people with all types of MS. 

Back to top

Page tagged with:
Page last updated: 14 Aug 2017

What's new?